Search details
1.
Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys.
Drug Dev Ind Pharm
; 45(3): 387-394, 2019 Mar.
Article
in English
| MEDLINE | ID: mdl-30395728
2.
A metabolic regulator modulates virulence and quorum sensing signal production in Pectobacterium atrosepticum.
Mol Plant Microbe Interact
; 26(3): 356-66, 2013 Mar.
Article
in English
| MEDLINE | ID: mdl-23113713
3.
Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease.
Sci Rep
; 11(1): 19422, 2021 09 30.
Article
in English
| MEDLINE | ID: mdl-34593832
4.
The rsmS (ybaM) mutation causes bypass suppression of the RsmAB post-transcriptional virulence regulation system in enterobacterial phytopathogens.
Sci Rep
; 9(1): 4525, 2019 03 14.
Article
in English
| MEDLINE | ID: mdl-30872786
5.
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients.
Sci Rep
; 9(1): 14042, 2019 10 01.
Article
in English
| MEDLINE | ID: mdl-31575982
6.
Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease.
Sci Rep
; 8(1): 4941, 2018 03 21.
Article
in English
| MEDLINE | ID: mdl-29563546
Results
1 -
6
de 6
1
Next >
>>